Damora Therapeutics is trading 5.49% down at $28.92, with no clear company-specific announcement or catalyst identified for August 28, 2026.
- Its investor-relations release list shows latest updates dated August 10 and August 5, covering second-quarter results and CLARITY-101 trial initiation.
- Broader markets are nearly flat as investors assess hawkish Federal Reserve commentary and mixed sentiment, providing limited evidence for a direct explanation of the decline.